Takeda Pharmaceutical (NYSE:TAK) Issues Earnings Results

Takeda Pharmaceutical (NYSE:TAK) issued its earnings results on Wednesday. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.36, Zacks reports. The business had revenue of $28.19 billion for the quarter, compared to the consensus estimate of $7.14 billion. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.23%. Takeda Pharmaceutical updated its FY 2026 guidance to 3.009-3.009 EPS.

Here are the key takeaways from Takeda Pharmaceutical’s conference call:

• Takeda said fiscal 2025 was a strong year for its pipeline, with positive Phase III data for oveporexton, rusfertide and zasocitinib, plus positive pivotal results for TAK-881. Management framed these as setting up multiple near-term launches and a broader late-stage pipeline with significant long-term potential.
• FY2025 core revenue was about JPY 4.5 trillion and core operating profit was JPY 1.17 trillion, with results pressured by Vyvanse generic erosion but supported by disciplined cost control. Core EPS still grew 3.1% at constant currency, and free cash flow remained strong at JPY 684.5 billion.
• The company highlighted three major launches expected within the next 12 months: oveporexton for narcolepsy type 1, rusfertide for polycythemia vera, and zasocitinib for psoriasis. Takeda said all three have priority review status or equivalent momentum and could become future blockbuster brands.
• FY2026 guidance calls for low-single-digit revenue decline and core operating profit down 5% to 8% at constant exchange rates, as Takeda invests heavily in launches and R&D. The company also expects about JPY 170 billion of restructuring costs and roughly 4,500 roles impacted by its transformation program.
• Management said its new transformation program should deliver more than JPY 200 billion of annualized gross savings by FY2028, supporting a return to growth and helping fund future launches. Takeda also plans to increase the annual dividend to JPY 204 per share and continue deleveraging toward a 2x net debt/EBITDA target.

Takeda Pharmaceutical Stock Down 0.1%

Shares of NYSE TAK traded down $0.02 during midday trading on Friday, reaching $16.61. 2,789,063 shares of the company’s stock traded hands, compared to its average volume of 3,043,384. The company has a quick ratio of 0.65, a current ratio of 1.19 and a debt-to-equity ratio of 0.56. The stock’s 50 day simple moving average is $17.62 and its 200-day simple moving average is $16.41. Takeda Pharmaceutical has a one year low of $12.99 and a one year high of $18.90. The company has a market cap of $52.86 billion, a price-to-earnings ratio of 9.67 and a beta of -0.06.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 11th. Sanford C. Bernstein upgraded shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Takeda Pharmaceutical in a research note on Wednesday, April 29th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Takeda Pharmaceutical has a consensus rating of “Moderate Buy”.

Institutional Investors Weigh In On Takeda Pharmaceutical

Hedge funds and other institutional investors have recently bought and sold shares of the company. Parkside Financial Bank & Trust lifted its position in Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after acquiring an additional 1,684 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in Takeda Pharmaceutical by 313.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after acquiring an additional 2,328 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in Takeda Pharmaceutical by 56.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after acquiring an additional 1,292 shares during the last quarter. Advisory Services Network LLC purchased a new stake in Takeda Pharmaceutical during the third quarter valued at approximately $74,000. Finally, Kestra Advisory Services LLC purchased a new stake in Takeda Pharmaceutical during the fourth quarter valued at approximately $101,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.